Free tool
FAERS Monitor: Vancomycin Hydrochloride
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209481 or its brand name (Vancomycin Hydrochloride, Vancomycin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,339
Serious
6,612
90% of reports
Hospitalization
3,189
Death reported
1,453
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective850
- acute kidney injury498
- off label use460
- pyrexia433
- rash309
- drug reaction with eosinophilia and systemic symptoms300
- drug hypersensitivity289
- condition aggravated267
- pneumonia262
- diarrhoea255
- sepsis252
- hypotension225
- pruritus203
- dyspnoea202
- renal failure202
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 51 |
| 2006 | 82 |
| 2007 | 150 |
| 2008 | 270 |
| 2009 | 99 |
| 2010 | 91 |
| 2011 | 106 |
| 2012 | 152 |
| 2013 | 196 |
| 2014 | 154 |
| 2015 | 265 |
| 2016 | 160 |
| 2017 | 180 |
| 2018 | 265 |
| 2019 | 387 |
| 2020 | 419 |
| 2021 | 628 |
| 2022 | 916 |
| 2023 | 918 |
| 2024 | 771 |
| 2025 | 653 |
| 2026 | 364 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,820 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug reaction with eosinophilia and systemic symptomsSignal | 300 | 33.8 | 30.2 | 9,416 |
| acute kidney injurySignal | 498 | 9.4 | 8.6 | 3,722 |
| sepsisSignal | 252 | 6.5 | 5.7 | 1,168 |
| renal failureSignal | 202 | 4.4 | 3.8 | 523 |
| drug hypersensitivitySignal | 289 | 4.3 | 3.8 | 730 |
| pyrexiaSignal | 433 | 3.6 | 3.3 | 819 |
| hypotensionSignal | 225 | 3.2 | 2.8 | 344 |
| condition aggravatedSignal | 267 | 2.5 | 2.2 | 246 |
| pneumoniaSignal | 262 | 2.3 | 2.1 | 198 |
| rashSignal | 309 | 2.0 | 1.8 | 164 |
| drug ineffective | 850 | 1.8 | 1.7 | 352 |
| pruritus | 203 | 1.5 | 1.3 | 36 |
| off label use | 460 | 1.5 | 1.4 | 81 |
| diarrhoea | 255 | 1.1 | 1.0 | 4 |
| dyspnoea | 202 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.